PRDM14 siRNA therapy (Nano RNA/Keio University)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NamePRDM14 siRNA therapy (Nano RNA/Keio University)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionPR Domain Zinc Finger Protein 14 modulators
TargetsPR Domain Zinc Finger Protein 14
Therapy Area/IndicationsHR-positive breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNANO MRNA Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNANO MRNA Co LtdKeio University
Inactive CompaniesN/A
Active IndicationsHR-positive breast cancer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A